ERBB2 and non-small cell lung carcinoma: He demonstrated sustained SD over 14 cycles, aligning with the promising outcomes observed in clinical trials, which provided essential insights into the potential efficacy of T-DXd in the first line treatment for HER2 mutant NSCLC.